Bern researcher viewing sample)

Research & Development

Innovation is in Our DNA

Innovation is in our DNA and is the core of everything we do at CSL Behring. Our team of over 1,700 R&D experts are dedicated to developing and delivering new therapies to solve unmet medical needs and save lives. We have created one of the largest and most efficient plasma collection networks in the world and strive to be the best at delivering safe and effective medicines for our patients.

  • US $832 million

    was invested in R&D in 2018/19 (incl. Seqirus)

  • US $3.3 billion

    in R&D investments in the last 5 years (incl. Seqirus)

  • >1,700

    research & development employees

Female Scientist at Broadmeadows

Investment in our R&D

Investment in R&D is an important driver for CSL Behring’s future growth. We have a high quality and potentially valuable portfolio of projects in various stages of development. We continue to make a balanced investment in the life cycle management and market development of existing products that bring short to mid-term commercial benefits, and we make strategic investments in longer term, higher risk and high opportunity new product development activities.

Find a Clinical Trial

A clinical trial is a research study that is done to find out if medical treatments can improve people’s health. A medical treatment can be a drug, medical device, medical procedure, or a change in a person’s behavior such as diet or exercise. People who take part in clinical trials are volunteers. They are also called “participants."

Therapeutic Area Condition Description
Haematology and Thrombosis
Hemophilia A CSL627_3001: An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A. Learn More
Hemophilia B CSL654_3003: A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B Learn More
Hemophilia A & B CSL689_2001: Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors Terminated
Congenital Fibrinogen Deficiency BI3023_4003: An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency Completed
Von Willebrand Disease CSLCT-BIO-12-83: Study of Voncento® in Subjects With Von Willebrand Disease Completed
Reversal of acquired coagulation factor deficiency BE1116_4001: An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding Learn More
  Sickle Cell CSL200_1001: CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease Learn More
Cardiovascular and Metabolic Acute Coronary Syndrome CSL112_3001: Study to investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II) Learn More
  Coronary Heart Disease CSL112_1001: Assessing the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian adults Completed
Immunology and Neurology Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) IgPro20_3004: Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Results
  Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) IgPro10_5004: Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP (HELIPAD 1) Learn More
  Dermatomyositis (DM) IgPro20_3007: A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with Dermatomyositis (DM) Learn More
  Pediatric CIDP IgPro10_4002: Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Learn More
  Hereditary Angioedema (HAE) CSL312_2001: A study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) Learn More
  Primary Immune Deficiency (PID) IgPro20_4004: Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra®) in Subjects With Primary Immunodeficiency (PID) Completed
Primary Immune Deficiency (PID) IgPro20_4005: Study of Immune Deficiency Patients treated with Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules Results
  Primary Immune Deficiency (PID) IgPro20_1001: Comparison of 2 Infusion Devices With Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra: An Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump Learn More
  Healthy Subjects CSL730_1001: Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults Learn More
Healthy Subjects CSL324_1001: Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults Completed
Respiratory Mild Asthma CSL311_1001: A Clinical Study to test the safety, exposure, and markers of Efficacy of CSL311 in patients with mild asthma. Learn More
Transplant Antibody-mediated kidney transplant rejection CSL842_3001: Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients Learn More
  Acute GVHD (aGVHD) CSL964_2001: The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE) Learn More

World-Class R&D Network

CSL is a global specialty biotech with a strong commitment to funding research and development of medicines to support its continued growth. We operate as one integrated global research and development organization that assembles coordinated global project teams, drawing together staff from different countries depending on their expertise. Our teams rely on a project management framework that facilitates collaboration across national and cultural boundaries.

CSL Parkville office

CSL Limited
Global Corporate HQ
R&D and Manufacturing

CSL Behring
R&D and Manufacturing

Bio21 Global Research and Translational Medicine Hub

Marburg employees

CSL Behring
R&D and Manufacturing

Kankakee office
United States

CSL Behring
Head Office and R&D

CSL Behring
R&D and Manufacturing


Bern, Switzerland

CSL Behring
R&D and Manufacturing

Researchers taking notes

CSL Behring

Asian male and caucasian female in a lab

R&D and Manufacturing

R&D Briefings Archives

December 2018 pdf
December 2017 pdf
December 2016 pdf
December 2015 pdf
December 2014 pdf
Product Pipeline

Innovation is in our DNA; Learn more about what's in our pipeline.

Learn More
Clinical Trials

Find out how to participate.

Learn More
Job Opportunities

Join us and make history with the brightest, most passionate people from every discipline.

Learn More

Get our latest Vita stories in your inbox
First name
Last name


You have now been added
to the CSL Behring Vita list